Sovesudil

Sovesudil (PHP-201) 是一种有效的、ATP 竞争性局部作用 Rho激酶 (ROCK) 抑制剂，对 ROCK I 和 ROCK II 的 IC50 分别为 3.7 和 2.3 nM。Sovesudil 降低眼压而不引起充血。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥5400.00

4320.00

- +
10mg

￥9175.00

7340.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx35512
CAS: 1333400-14-8
别名: PHP-201; AMA0076
分子式: C23H22FN3O3
分子量: 407.44
纯度: >98%
溶解度: DMSO : 100 mg/mL (245.43 mM; Need ultrasonic)
储存: Store at -20°C
库存: 现货

Background

Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia[1][2].

Sovesudil (PHP-201) (1 μM; 60 min) is able to induce altered cellular behavior of human trabecular meshwork (HTM) cells[1].

Sovesudil (0.1%, 0.3%, and 0.5%; male New Zealand White rabbits) effectively reduces Intraocular Pressure (IOP) in ocular normotensive and acute hypertensive rabbits without causing distinct hyperemia[1].

[1]. Van de Velde S, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55(2):1006-1016. Published 2014 Feb 18. [2]. Ha A, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study [published online ahead of print, 2021 Jul 28]. Acta Ophthalmol. 2021;10.1111/aos.14949.